«Ульяновский медико-биологический журнал»

REVIEWS

Download article

УДК 618.17

DOI 10.34014/2227-1848-2023-4-21-37

PREMENSTRUAL SYNDROME: BASIC APPROACHES TO TREATMENT

M.A. Kiek

Medical Center “21st Century”, St. Petersburg, Russia

 

Premenstrual syndrome (PMS) is a common neuroendocrine pathology. PMS has a significant impact on the women’s lives. It negatively affects the psychophysiological state, social functioning, reduces ability to work and quality of life. Therefore, it has great medical and social significance. According to numerous studies, PMS prevalence ranges from 25 % to 80 %. PMS clinical picture is characterized by a variety of mental and somatic symptoms of varying severity, that leads to certain difficulties in choosing therapy. Currently, there are no clinical guidelines for the diagnosis and treatment of this pathology in Russia. The task of practitioners is to find the most effective, safe and pathogenetically justified treatment modes, based on an individual approach depending on the clinical manifestations of the disease.

The review presents the results of various PMS treatment modalities, presented in eLibrary.ru, Pubmed, SpringerLink, APA PsycNET, ScienceDirect, and Google Scholar. Current experience shows that PMS therapy should be carried out comprehensively. In order to achieve and maintain good results, it is advisable to combine drug therapy with cognitive behavioral therapy, physical therapy and physiotherapy.

PMS is an interdisciplinary problem, so it should be treated by various specialists. It is important to differentiate between PMS, somatic pathology and affective states. A large scope of treatment modalities does not exclude the patients who do not respond to therapy. It proves the need for further study of the disease pathogenesis and the development of preventive measures with respect to modern medical advances.

Key words: premenstrual syndrome, treatment modalities.

 

Conflict of interest. The author declares no conflicts of interest.

References

  1.  Nevatte T., O'Brien P.M., Bäckström T., Brown C., Dennerstein L., Endicott J., Epperson C.N., Eriksson E., Freeman E.W., Halbreich U., Yonkers K. Consensus Group of the International Society for Premenstrual Disorders. ISPMD consensus on the management of premenstrual disorders. Arch. Womens. Ment. Health. 2013; 4: 279–291. DOI: 10.1007/s00737-013-0346-y.

  2.  Ismaili E., Walsh S., O'Brien P.M.S., Bäckström T., Brown C., Dennerstein L., Eriksson E., Freeman E.W., Ismail K.M.K., Panay N., Yonkers K. Consensus Group of the International Society for Premenstrual Disorders. Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder. Arch. Womens. Ment. Health. 2016; 19 (6): 953–958. DOI: 10.1007/s00737-016-0631-7.

  3. Geta T.G., Woldeamanuel G.G., Dassa T.T. Prevalence and associated factors of premenstrual syndrome among women of the reproductive age group in Ethiopia: Systematic review and meta-analysis. PLoS. One. 2020; 15 (11): e0241702. DOI: 10.1371/journal.pone.0241702.

  4. Belokrinitskaya T.E., Frolova N.I., Belozertseva E.P. Dismenoreya, predmenstrual'nyy sindrom i sindrom predmenstrual'nogo disforicheskogo rasstroystva u devushek-studentok [Dysmenorrhea, premenstrual syndrome and premenstrual dysphoric disorder syndrome in female students]. Reproduktivnoe zdorov'e detey i podrostkov. 2012; 1: 22–28 (in Russian).

  5. Yoshimi K., Matsumura N., Takeda T. When and how do adolescent girls in Japan become aware of premenstrual symptoms from menarche? A cross-sectional study among senior high school students. BMJ Open. 2021; 11 (8): e045215. DOI: 10.1136/bmjopen-2020-045215.

  6. Green L.J., O’Brien P.M.S., Panay N., Craig M. Management of Premenstrual Syndrome: Green-top Guideline No. 48. BJOG. 2017; 124 (3): e73–e105. DOI: 10.1111/1471-0528.14260.

  7. O'Brien P.M.S., Rapkin A., Schmidt P.J., eds. The Premenstrual Syndromes: PMS and PMDD. 1st ed. London: CRC Press; 2007. 204. DOI: https://doi.org/10.3109/9781435628168.

  8. Duko B., Mekuriaw B., Molla A., Ayano G. The prevalence of premenstrual dysphoric disorder among adolescents in Ethiopia: a systematic review and meta-analysis. Ir. J. Med. Sci. 2021; 190 (1): 419–427. DOI: 10.1007/s11845-020-02275-7.

  9. Aganezova N.V. Rol' nasledstvennykh i gormonal'nykh faktorov v razvitii predmenstrual'nogo sindroma [Role of hereditary and hormonal factors in the development of premenstrual syndrome]. Zhurnal akusherstva i zhenskikh bolezney. 2011; 1 (60): 12–20 (in Russian).

  10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-V). 5th ed. Washington DC: APA; 2013.

  11. Frank R.T. The hormonal causes of premenstrual tension. Arch. Neurol. Psychiatry. 1931; 26: 1053–1057.

  12. Ivanov G.P., Gorobets L.N., Litvinov A.V., Bulanov V.S., Vasilenko L.M. Rol' progesterona i ego metabolitov v regulyatsii funktsiy golovnogo mozga [Role of progesterone and its metabolites in the regulation functions of the brain]. Zhurnal nevrologii i psikhiatrii. 2018; 5: 129–137. DOI: 10.17116/jnevro201811851129 (in Russian).

  13.  Finocchi C., Ferrari M. Female reproductive steroids and neuronal excitability. Neurol. Sci. 2011; 32 (suppl. 1): S31–S35. DOI: 10.1007/s10072-011-0532-5.

  14. Hantsoo L., Epperson C.N. Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle. Neurobiol. Stress. 2020; 12: 100213. DOI: 10.1016/j.ynstr.2020.100213.

  15. Halbreich U. The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology. 2003; 28 (suppl. 3): 55–99. DOI: 10.1016/S0306-4530(03)00097-0.

  16. Studd J. Ovariotomy for menstrual madness and premenstrual syndrome – 19th century history and lessons for current practice. Gynecol. Endocrinol. 2006; 22 (8): 411–415. DOI: 10.1080/09513590600881503.

  17.  Casson P., Hahn P.M., Van Vugt D.A., Reid R.L. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am. J. Obstet. Gynecol. 1990; 162 (1): 99–105. DOI: 10.1016/0002-9378(90)90830-z.

  18. Cronje W.H., Vashisht A., Studd J.W. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum. Reprod. 2004; 19 (9): 2152–2155. DOI: 10.1093/humrep/deh354.

  19. Casper R.F., Hearn M.T. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. Am. J. Obstet. Gynecol. 1990; 162 (1): 105–109. DOI: 10.1016/0002-9378(90)90831-q.

  20. Larun L., Brurberg K.G., Odgaard-Jensen J., Price J.R. Exercise therapy for chronic fatigue syndrome. Cochrane Database Syst Rev. 2015; 2: CD003200. DOI: 10.1002/14651858.CD003200.pub3.

  21. Mohebbi Dehnavi Z., Jafarnejad F., Sadeghi Goghary S. The effect of 8 weeks aerobic exercise on severity of physical symptoms of premenstrual syndrome: a clinical trial study. BMC Womens Health. 2018; 18 (1): 80. DOI: 10.1186/s12905-018-0565-5.

  22. Maged A.M., Abbassy A.H., Sakr H.R.S. Effect of swimming exercise on premenstrual syndrome. Arch. Gynecol. Obstet. 2018; 297 (4): 951–959. DOI: 10.1007/s00404-018-4664-1.

  23. Witkoś J., Hartman-Petrycka M. The Influence of Running and Dancing on the Occurrence and Progression of Premenstrual Disorders. Int. J. Environ. Res. Public. Health. 2021; 18 (15): 7946. DOI: 10.3390/ijerph18157946.

  24. Tsai S.Y. Effect of Yoga Exercise on Premenstrual Symptoms among Female Employees in Taiwan. Int. J. Environ. Res. Public. Health. 2016; 13 (7): 721. DOI: 10.3390/ijerph13070721.

  25. Manukhin I.B., Tumilovich L.G., Gevorkyan M.A., Manukhina E.I. Ginekologicheskaya endokrinologiya [Gynecological endocrinology]. Klinicheskie lektsii. 4-e izd., pererab. i dop. Moscow: GEOTAR-Media; 2017. 304 (in Russian).

  26. Kwon Y.J., Sung D.I., Lee J.W. Association among Premenstrual Syndrome, Dietary Patterns, and Adherence to Mediterranean Diet. Nutrients. 2022; 14 (12): 2460. DOI: 10.3390/nu14122460.

  27. Rogozhina I.E., Ignatova V.B. Rol' serotoninovoy sistemy v proyavlenii predmenstrual'nogo sindroma [Role of the serotonin system in the manifestation of premenstrual syndrome]. Saratovskiy nauchno-meditsinskiy zhurnal. 2016; 12 (2): 136–138 (in Russian).

  28. Jang S.H., Kim D.I., Choi M.S. Effects and treatment methods of acupuncture and herbal medicine for premenstrual syndrome/premenstrual dysphoric disorder: systematic review. BMC Complement. Altern. Med. 2014; 14: 11. DOI: 10.1186/1472-6882-14-11.

  29.  Aganezova N.V., Vovk A.V., Slivankova E.V., Linde V.A., Shabalina A.Yu., Krinits'sha E.L. Klinicheskiy opyt primeneniya transkranial'noy elektrostimulyatsii u patsientok s predmenstrual'nym sindromom [Clinical experience of using transcranial electrical stimulation in patients with premenstrual syndrome]. Nelekarstvennaya meditsina. 2006; 1: 37–38 (in Russian).

  30. Busse J.W., Montori V.M., Krasnik C., Patelis-Siotis I., Guyatt G.H. Psychological intervention for premenstrual syndrome: a meta-analysis of randomized controlled trials. Psychother. Psychosom. 2009; 78: 6–15.

  31. Chocano-Bedoya P.O., Manson J.E., Hankinson S.E., Willett W.C., Johnson S.R., Chasan-Taber L., Ronnenberg A.G., Bigelow C., Bertone-Johnson E.R. Dietary B vitamin intake and incident premenstrual syndrome. Am. J. Clin. Nutr. 2011; 93 (5): 1080–1086. DOI: 10.3945/ajcn.110.009530.

  32. Thys-Jacobs S., Starkey P., Bernstein D., Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am. J. Obstet. Gynecol. 1998; 179 (2): 444–452. DOI: 10.1016/s0002-9378(98)70377-1.

  33. Bharati M. Comparing the Effects of Yoga & Oral Calcium Administration in Alleviating Symptoms of Premenstrual Syndrome in Medical Undergraduates. J. Caring. Sci. 2016; 5 (3): 179–185. DOI: 10.15171/jcs.2016.019.

  34. Rakhmatova D., Karomatov I.D. Fitoterapiya v profilaktike i lechenii predmenstrual'nogo sindroma [Herbal medicine in PMS prevention and treatment]. Biologiya i integrativnaya meditsina. 2018; 11 (28): 93–104 (in Russian).

  35. Vysotskaya I.V., Letyagin V.P. Farmakologicheskie effekty i molekulyarnye mekhanizmy deystviya lechebnogo fitopreparata na osnove Vitex agnus-castus [Pharmacological effects and molecular mechanisms of action of herbal medicine based on Vitex agnus-castus]. Opukholi zhenskoy reproduktivnoy sistemy. 2017; 13 (1): 14–19. DOI: 10.17650/1994-4098-2017-13-1-14-19 (in Russian).

  36. Alamov G.V., Mel'nikov E.S., Lupanov I.A., Radimich A.I., Saybel' O.L. Izuchenie khimicheskogo sostava dofaminergicheskoy aktivnosti plodov viteksa svyashchennogo (Vitex agnus-castus L.) [Investigation of the chemical composition and dopaminergic activity of the Vitex Agnus-castus fruits]. Razrabotka i registratsiya lekarstvennykh sredstv. 2020; 9 (3): 134–149. DOI: 10.33380/2305-2066-2020-9-3-143-149 (in Russian).

  37.  Webster D.E., Lu J., Chen S.N., Farnsworth N.R., Wang Z.J. Activation of the mu-opiate receptor by Vitex agnus-castus methanol extracts: implication for its use in PMS. J. Ethnopharmacol. 2006; 106 (2): 216–221. DOI: 10.1016/j.jep.2005.12.025.

  38. Dante G., Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. J. Psychosom. Obstet. Gynaecol. 2011; 32 (1): 42–51. DOI: 10.3109/0167482X.2010.538102.

  39. Cerqueira R.O., Frey B.N., Leclerc E., Brietzke E. Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch. Womens. Ment. Health. 2017; 20 (6): 713–719. DOI: 10.1007/s00737-017-0791-0.

  40. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ. 2001; 322 (7279): 134–137. DOI: 10.1136/bmj.322.7279.134.

  41. Verkaik S., Kamperman A.M., van Westrhenen R., Schulte P.F.J. The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis. Am. J. Obstet. Gynecol. 2017; 217 (2): 150–166. DOI: 10.1016/j.ajog.2017.02.028.

  42. Kulakov V.I. Ratsional'naya farmakoterapiya v akusherstve i ginekologii: Rukovodstvo dlya vrachey [Rational pharmacotherapy in obstetrics and gynecology: Physician’s guidelines]. Moscow: LITTERRA; 2015. 750 (in Russian).

  43.  Brown C.S., Ling F.W., Andersen R.N., Farmer R.G., Arheart K.L. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet. Gynecol. 1994; 84 (5): 779–786.

  44. Freeman E.W., Sondheimer S.J., Rickels K. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol. Bull. 1997; 33 (2): 303–309.

  45. Di Carlo C., Tommaselli G.A., Gargano V., Savoia F., Bifulco G., Nappi C. Transdermal estradiol and oral or vaginal natural progesterone: bleeding patterns. Climacteric. 2010; 13 (5): 442–446. DOI: 10.3109/13697137.2010.490605.

  46. Elovainio M., Teperi J., Aalto A. M., Grenman S., Kivelä A., Kujansuu E., Vuorma S., Yliskoski M., Paavonen J., Hurskainen R. Depressive symptoms as predictors of discontinuation of treatment of menorrhagia by levonorgestrel-releasing intrauterine system. Int. J. Behav. Med. 2007; 14 (2): 70–75. DOI: 10.1007/BF03004171.

  47. Watson N.R., Studd J.W., Savvas M., Garnett T., Baber R.J. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet. 1989; 2 (8665): 730–732. DOI: 10.1016/s0140-6736(89)90784-8.

  48. Watson N.R., Studd J.W., Savvas M., Baber R.J. The long-term effects of estradiol implant therapy for the treatment of premenstrual syndrome. Gynecol. Endocrinol. 1990; 4 (2): 99–107. DOI: 10.3109/09513599009012326.

  49. Prilepskaya V.N. Gormonal'naya kontratseptsiya: Klinicheskie lektsii [Hormonal contraception: Clinical lectures]. Moscow: GEOTAR-Media; 2014. 256 (in Russian).

  50. Tatarchuk. T.F. Predmenstrual'nyy sindrom [Premenstrual syndrome]. V kn.: Tatarchuk T.F., Ventskovskaya I.B., Shevchuk T.V. Endokrinnaya ginekologiya [Endocrine gynecology]. Kiev: Zapovit; 2003: 111–146 (in Russian).

  51. Wyatt K., Dimmock P., Jones P., Obhrai M., O'Brien S. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ. 2001; 323 (7316): 776–780. DOI: 10.1136/bmj.323.7316.776.

  52.  Lopez L.M., Kaptein A.A., Helmerhorst F.M. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2012; 2: CD006586. DOI: 10.1002/14651858.CD006586.pub4.

  53. Pearlstein T.B., Bachmann G.A., Zacur H.A., Yonkers K.A. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005; 72 (6): 414–421. DOI: 10.1016/j.contraception.2005.08.021.

  54. Dilbaz B., Aksan A. Premenstrual syndrome, a common but underrated entity: review of the clinical literature. J. Turk. Ger. Gynecol. Assoc. 2021; 22 (2): 139–148. DOI: 10.4274/jtgga.galenos.2021.2020.0133.

  55.  Loginova K.B., Dyukova G.M., Dobrokhotova Yu.E. Lechenie predmenstrual'nogo sindroma i predmenstrual'nykh disforicheskikh rasstroystv kombinirovannymi oral'nymi kontratseptivami [Treatment of premenstrual syndrome and premenstrual dysphoric disorders with combined oral contraceptives]. Meditsinskiy alfavit. 2018; 33 (4): 13–16 (in Russian).

  56. Aganezova N.V., Linde V.A. Differentsirovannyy podkhod k terapii predmenstrual'nogo sindroma monofaznymi kombinirovannymi kontratseptivami [Differentiated approach to PMS treatment with monophasic combined contraceptives]. Zhurnal akusherstva i zhenskikh bolezney. 2008; 57 (2): 43–52 (in Russian).

  57.  Aganezova N.V. Terapiya predmenstrual'nogo sindroma estrogen-gestagennym preparatom, soderzhashchim 20 mkg etinilestradiola i 3 mg drospirenona [PSM treatment with an estrogen-progestogen drug containing 20 mcg ethinyl estradiol and 3 mg drospirenone]. Zhurnal akusherstva i zhenskikh bolezney. 2011; 60 (1): 97–104 (in Russian).

  58. Nazarova N.M., Prilepskaya V.N. Estrogen-gestagennye rilizing-sistemy: novyy vzglyad na kontratseptsiyu (obzor literatury) [Estrogen-progestogen releasing systems: New look at contraception (literature review)]. Farmateka. 2009; 14: 10–15 (in Russian).

  59. Milsom I., Lete I., Bjertnaes A., Rokstad K., Lindh I., Gruber C.J., Birkhäuser M.H., Aubeny E., Knudsen T., Bastianelli C. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 µg ethinyl estradiol and 3 mg drospirenone. Human. Reproduction. 2006; 21 (9): 2304–2311. DOI: 10.1093/humrep/del162.

  60. Marjoribanks J., Brown J., O'Brien P.M., Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2013; 2013 (6): CD001396. DOI: 10.1002/14651858.CD001396.pub3.

  61. Freeman E.W., Rickels K., Yonkers K.A., Kunz N.R., McPherson M., Upton G.V. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet. Gynecol. 2001; 98 (5, Pt 1): 737–744. DOI: 10.1016/s0029-7844(01)01530-7.

  62. Pearlstein T.B., Stone A.B., Lund S.A., Scheft H., Zlotnick C., Brown W.A. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J. Clin. Psychopharmacol. 1997; 17 (4): 261–266. DOI: 10.1097/00004714-199708000-00004.

  63. Freeman E.W., Rickels K., Sondheimer S.J., Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch. Gen. Psychiatry. 1999; 56 (10): 932–939. DOI: 10.1001/archpsyc.56.10.932.

  64. Eriksson E., Hedberg M.A., Andersch B., Sundblad C. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology. 1995; 12 (2): 167–176. DOI: 10.1016/0893-133X(94)00076-C.

  65.  Brown J., O'Brien P.M., Marjoribanks J., Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2009; 2: CD001396. DOI: 10.1002/14651858.CD001396.pub2.

  66. Dimmock P.W., Wyatt K.M., Jones P.W., O'Brien P.M. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet. 2000; 356 (9236): 1131–1136. DOI: 10.1016/s0140-6736(00)02754-9.

  67. Landén M., Nissbrandt H., Allgulander C., Sörvik K., Ysander C., Eriksson E. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology. 2007; 32 (1): 153–161. DOI: 10.1038/sj.npp.1301216.

  68. Solov'eva A.D., Buyachinskaya A.I. Grandaksin v lechenii predmenstrual'nogo sindroma [Grandaxin in PMS treatment]. Lechenie nervnykh bolezney. 2001; 2 (3): 29–31 (in Russian).

 Received February 08, 2023; accepted July 10, 2023.

 

Information about the author

Kiek Marina Aleksandrovna, Obstetrician-Gynecologist, Medical Center “21st Century”. 194044, Russia, St. Petersburg, Bol'shoy Sampsonievskiy Ave., 45; e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра., ORCID ID: https://orcid.org/0000-0002-1539-2559

 

For citation

Kiek M.A. Predmenstrual'nyy sindrom: osnovnye podkhody k lecheniyu [Premenstrual syndrome: Basic approaches to treatment]. Ul'yanovskiy mediko-biologicheskiy zhurnal. 2023; 4: 21–37. DOI: 10.34014/2227-1848-2023-4-21-37 (in Russian).

 

 

Скачать статью 

УДК 618.17

DOI 10.34014/2227-1848-2023-4-21-37

ПРЕДМЕНСТРУАЛЬНЫЙ СИНДРОМ: ОСНОВНЫЕ ПОДХОДЫ К ЛЕЧЕНИЮ

М.А. Киёк

ООО «Медицинский центр «XXI век», г. Санкт-Петербург, Россия

 

Одной из распространенных нейроэндокринных патологий является предменструальный синдром (ПМС). ПМС оказывает значительное влияние на все сферы жизни женщин, отрицательно сказывается на психофизиологическом состоянии, социальном функционировании, снижает трудоспособность и качество жизни, в связи с чем имеет большое медико-социальное значение. Распространенность ПМС, по данным многочисленных исследований, составляет от 25 % до 80 %. Клиническая картина ПМС характеризуется многообразием психических и соматических симптомов разной степени выраженности, что создает определенные трудности в выборе терапии. В настоящее время в России не разработаны клинические рекомендации по диагностике и лечению данной патологии. Задачей практикующих врачей является поиск наиболее эффективных, безопасных в отношении репродуктивного здоровья и патогенетически оправданных методов лечения, основанных на индивидуальном подходе в зависимости от клинических проявлений заболевания.

В обзоре отражены результаты исследований различных методов лечения ПМС, представленных в базах eLibrary.ru, Pubmed, SpringerLink, APA PsycNET, ScienceDirect, Google Scholar. Накопленный опыт показывает, что терапия ПМС должна осуществляться комплексно. Для достижения и поддержания хороших результатов медикаментозную терапию целесообразно сочетать с когнитивно-поведенческой терапией, лечебной физкультурой и физиотерапией.

ПМС – междисциплинарная проблема, которую необходимо решать с участием смежных специалистов. Важно дифференцировать ПМС, соматическую патологию и аффективные состояния. Большой выбор методов лечения не исключает наличия пациенток, не отвечающих на терапию, что диктует необходимость дальнейшего изучения особенностей патогенеза заболевания и разработки профилактических мероприятий с учетом современных достижений медицины.

Ключевые слова: предменструальный синдром, методы лечения.

 

Конфликт интересов. Автор заявляет об отсутствии конфликтов интересов.

 

Литература

  1. Nevatte T., O'Brien P.M., Bäckström T., Brown C., Dennerstein L., Endicott J., Epperson C.N., Eriksson E., Freeman E.W., Halbreich U., Yonkers K. Consensus Group of the International Society for Premenstrual Disorders. ISPMD consensus on the management of premenstrual disorders. Arch. Womens. Ment. Health. 2013; 4: 279–291. DOI: 10.1007/s00737-013-0346-y.

  2. Ismaili E., Walsh S., O'Brien P.M.S., Bäckström T., Brown C., Dennerstein L., Eriksson E., Freeman E.W., Ismail K.M.K., Panay N., Yonkers K. Consensus Group of the International Society for Premenstrual Disorders. Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder. Arch. Womens. Ment. Health. 2016; 19 (6): 953–958. DOI: 10.1007/s00737-016-0631-7.

  3. Geta T.G., Woldeamanuel G.G., Dassa T.T. Prevalence and associated factors of premenstrual syndrome among women of the reproductive age group in Ethiopia: Systematic review and meta-analysis. PLoS. One. 2020; 15 (11): e0241702. DOI: 10.1371/journal.pone.0241702.

  4. Белокриницкая Т.Е., Фролова Н.И., Белозерцева Е.П. Дисменорея, предменструальный синдром и синдром предменструального дисфорического расстройства у девушек-студенток. Репродуктивное здоровье детей и подростков. 2012; 1: 22–28.

  5. Yoshimi K., Matsumura N., Takeda T. When and how do adolescent girls in Japan become aware of premenstrual symptoms from menarche? A cross-sectional study among senior high school students. BMJ Open. 2021; 11 (8): e045215. DOI: 10.1136/bmjopen-2020-045215.

  6. Green L.J., O’Brien P.M.S., Panay N., Craig M. Management of Premenstrual Syndrome: Green-top Guideline No. 48. BJOG. 2017; 124 (3): e73–e105. DOI: 10.1111/1471-0528.14260.

  7. O'Brien P.M.S., Rapkin A., Schmidt P.J., eds. The Premenstrual Syndromes: PMS and PMDD. 1st ed. London: CRC Press; 2007. 204. DOI: https://doi.org/10.3109/9781435628168.

  8. Duko B., Mekuriaw B., Molla A., Ayano G. The prevalence of premenstrual dysphoric disorder among adolescents in Ethiopia: a systematic review and meta-analysis. Ir. J. Med. Sci. 2021; 190 (1): 419–427. DOI: 10.1007/s11845-020-02275-7.

  9.  Аганезова Н.В. Роль наследственных и гормональных факторов в развитии предменструального синдрома. Журнал акушерства и женских болезней. 2011; 1 (60): 12–20.

  10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-V). 5th ed. Washington DC: APA; 2013.

  11. Frank R.T. The hormonal causes of premenstrual tension. Arch. Neurol. Psychiatry. 1931; 26: 1053–1057.

  12. Иванов Г.П., Горобец Л.Н., Литвинов А.В., Буланов В.С., Василенко Л.М. Роль прогестерона и его метаболитов в регуляции функций головного мозга. Журнал неврологии и психиатрии. 2018; 5: 129–137. DOI: 10.17116/jnevro201811851129.

  13.  Finocchi C., Ferrari M. Female reproductive steroids and neuronal excitability. Neurol. Sci. 2011; 32 (suppl. 1): S31–S35. DOI: 10.1007/s10072-011-0532-5.

  14. Hantsoo L., Epperson C.N. Allopregnanolone in premenstrual dysphoric disorder (PMDD): Evidence for dysregulated sensitivity to GABA-A receptor modulating neuroactive steroids across the menstrual cycle. Neurobiol. Stress. 2020; 12: 100213. DOI: 10.1016/j.ynstr.2020.100213.

  15. Halbreich U. The etiology, biology, and evolving pathology of premenstrual syndromes. Psychoneuroendocrinology. 2003; 28 (suppl. 3): 55–99. DOI: 10.1016/S0306-4530(03)00097-0.

  16. Studd J. Ovariotomy for menstrual madness and premenstrual syndrome – 19th century history and lessons for current practice. Gynecol. Endocrinol. 2006; 22 (8): 411–415. DOI: 10.1080/09513590600881503.

  17. Casson P., Hahn P.M., Van Vugt D.A., Reid R.L. Lasting response to ovariectomy in severe intractable premenstrual syndrome. Am. J. Obstet. Gynecol. 1990; 162 (1): 99–105. DOI: 10.1016/0002-9378(90)90830-z.

  18.  Cronje W.H., Vashisht A., Studd J.W. Hysterectomy and bilateral oophorectomy for severe premenstrual syndrome. Hum. Reprod. 2004; 19 (9): 2152–2155. DOI: 10.1093/humrep/deh354.

  19. Casper R.F., Hearn M.T. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. Am. J. Obstet. Gynecol. 1990; 162 (1): 105–109. DOI: 10.1016/0002-9378(90)90831-q.

  20. Larun L., Brurberg K.G., Odgaard-Jensen J., Price J.R. Exercise therapy for chronic fatigue syndrome. Cochrane Database Syst Rev. 2015; 2: CD003200. DOI: 10.1002/14651858.CD003200.pub3.

  21. Mohebbi Dehnavi Z., Jafarnejad F., Sadeghi Goghary S. The effect of 8 weeks aerobic exercise on severity of physical symptoms of premenstrual syndrome: a clinical trial study. BMC Womens Health. 2018; 18 (1): 80. DOI: 10.1186/s12905-018-0565-5.

  22. Maged A.M., Abbassy A.H., Sakr H.R.S. Effect of swimming exercise on premenstrual syndrome. Arch. Gynecol. Obstet. 2018; 297 (4): 951–959. DOI: 10.1007/s00404-018-4664-1.

  23. Witkoś J., Hartman-Petrycka M. The Influence of Running and Dancing on the Occurrence and Progression of Premenstrual Disorders. Int. J. Environ. Res. Public. Health. 2021; 18 (15): 7946. DOI: 10.3390/ijerph18157946.

  24. Tsai S.Y. Effect of Yoga Exercise on Premenstrual Symptoms among Female Employees in Taiwan. Int. J. Environ. Res. Public. Health. 2016; 13 (7): 721. DOI: 10.3390/ijerph13070721.

  25. Манухин И.Б., Тумилович Л.Г., Геворкян М.А., Манухина Е.И. Гинекологическая эндокринология. Клинические лекции. 4-е изд., перераб. и доп. М.: ГЭОТАР-Медиа; 2017. 304.

  26. Kwon Y.J., Sung D.I., Lee J.W. Association among Premenstrual Syndrome, Dietary Patterns, and Adherence to Mediterranean Diet. Nutrients. 2022; 14 (12): 2460. DOI: 10.3390/nu14122460.

  27.  Рогожина И.Е., Игнатова В.Б. Роль серотониновой системы в проявлении предменструального синдрома. Саратовский научно-медицинский журнал. 2016; 12 (2): 136–138.

  28. Jang S.H., Kim D.I., Choi M.S. Effects and treatment methods of acupuncture and herbal medicine for premenstrual syndrome/premenstrual dysphoric disorder: systematic review. BMC Complement. Altern. Med. 2014; 14: 11. DOI: 10.1186/1472-6882-14-11.

  29. Аганезова Н.В., Вовк А.В., Сливанкова Е.В., Линде В.А., Шабалина А.Ю., Криницьша Е.Л. Клинический опыт применения транскраниальной электростимуляции у пациенток с предменструальным синдромом. Нелекарственная медицина. 2006; 1: 37–38.

  30. Busse J.W., Montori V.M., Krasnik C., Patelis-Siotis I., Guyatt G.H. Psychological intervention for premenstrual syndrome: a meta-analysis of randomized controlled trials. Psychother. Psychosom. 2009; 78: 6–15.

  31. Chocano-Bedoya P.O., Manson J.E., Hankinson S.E., Willett W.C., Johnson S.R., Chasan-Taber L., Ronnenberg A.G., Bigelow C., Bertone-Johnson E.R. Dietary B vitamin intake and incident premenstrual syndrome. Am. J. Clin. Nutr. 2011; 93 (5): 1080–1086. DOI: 10.3945/ajcn.110.009530.

  32. Thys-Jacobs S., Starkey P., Bernstein D., Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am. J. Obstet. Gynecol. 1998; 179 (2): 444–452. DOI: 10.1016/s0002-9378(98)70377-1.

  33. Bharati M. Comparing the Effects of Yoga & Oral Calcium Administration in Alleviating Symptoms of Premenstrual Syndrome in Medical Undergraduates. J. Caring. Sci. 2016; 5 (3): 179–185. DOI: 10.15171/jcs.2016.019.

  34. Рахматова Д., Кароматов И.Д. Фитотерапия в профилактике и лечении предменструального синдрома. Биология и интегративная медицина. 2018; 11 (28): 93–104.

  35. Высоцкая И.В., Летягин В.П. Фармакологические эффекты и молекулярные механизмы действия лечебного фитопрепарата на основе Vitex agnus-castus. Опухоли женской репродуктивной системы. 2017; 13 (1): 14–19. DOI: 10.17650/1994-4098-2017-13-1-14-19.

  36. Аламов Г.В., Мельников Е.С., Лупанов И.А., Радимич А.И., Сайбель О.Л. Изучение химического состава дофаминергической активности плодов витекса священного (Vitex agnus-castus L.). Разработка и регистрация лекарственных средств. 2020; 9 (3): 134–149. DOI: 10.33380/2305-2066-2020-9-3-143-149.

  37. Webster D.E., Lu J., Chen S.N., Farnsworth N.R., Wang Z.J. Activation of the mu-opiate receptor by Vitex agnus-castus methanol extracts: implication for its use in PMS. J. Ethnopharmacol. 2006; 106 (2): 216–221. DOI: 10.1016/j.jep.2005.12.025.

  38. Dante G., Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. J. Psychosom. Obstet. Gynaecol. 2011; 32 (1): 42–51. DOI: 10.3109/0167482X.2010.538102.

  39. Cerqueira R.O., Frey B.N., Leclerc E., Brietzke E. Vitex agnus castus for premenstrual syndrome and premenstrual dysphoric disorder: a systematic review. Arch. Womens. Ment. Health. 2017; 20 (6): 713–719. DOI: 10.1007/s00737-017-0791-0.

  40. Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ. 2001; 322 (7279): 134–137. DOI: 10.1136/bmj.322.7279.134.

  41. Verkaik S., Kamperman A.M., van Westrhenen R., Schulte P.F.J. The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis. Am. J. Obstet. Gynecol. 2017; 217 (2): 150–166. DOI: 10.1016/j.ajog.2017.02.028.

  42. Кулаков В.И. Рациональная фармакотерапия в акушерстве и гинекологии: Руководство для врачей. М.: ЛИТТЕРРА; 2015. 750.

  43. Brown C.S., Ling F.W., Andersen R.N., Farmer R.G., Arheart K.L. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. Obstet. Gynecol. 1994; 84 (5): 779–786.

  44. Freeman E.W., Sondheimer S.J., Rickels K. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study. Psychopharmacol. Bull. 1997; 33 (2): 303–309.

  45. Di Carlo C., Tommaselli G.A., Gargano V., Savoia F., Bifulco G., Nappi C. Transdermal estradiol and oral or vaginal natural progesterone: bleeding patterns. Climacteric. 2010; 13 (5): 442–446. DOI: 10.3109/13697137.2010.490605.

  46. Elovainio M., Teperi J., Aalto A. M., Grenman S., Kivelä A., Kujansuu E., Vuorma S., Yliskoski M., Paavonen J., Hurskainen R. Depressive symptoms as predictors of discontinuation of treatment of menorrhagia by levonorgestrel-releasing intrauterine system. Int. J. Behav. Med. 2007; 14 (2): 70–75. DOI: 10.1007/BF03004171.

  47. Watson N.R., Studd J.W., Savvas M., Garnett T., Baber R.J. Treatment of severe premenstrual syndrome with oestradiol patches and cyclical oral norethisterone. Lancet. 1989; 2 (8665): 730–732. DOI: 10.1016/s0140-6736(89)90784-8.

  48. Watson N.R., Studd J.W., Savvas M., Baber R.J. The long-term effects of estradiol implant therapy for the treatment of premenstrual syndrome. Gynecol. Endocrinol. 1990; 4 (2): 99–107. DOI: 10.3109/09513599009012326.

  49. Прилепская В.Н. Гормональная контрацепция: Клинические лекции. М.: ГЭОТАР-Медиа; 2014. 256.

  50. Татарчук. Т.Ф. Предменструальный синдром. В кн.: Татарчук Т.Ф., Венцковская И.Б., Шевчук Т.В. Эндокринная гинекология. Киев: Заповит; 2003: 111–146.

  51. Wyatt K., Dimmock P., Jones P., Obhrai M., O'Brien S. Efficacy of progesterone and progestogens in management of premenstrual syndrome: systematic review. BMJ. 2001; 323 (7316): 776–780. DOI: 10.1136/bmj.323.7316.776.

  52.  Lopez L.M., Kaptein A.A., Helmerhorst F.M. Oral contraceptives containing drospirenone for premenstrual syndrome. Cochrane Database Syst Rev. 2012; 2: CD006586. DOI: 10.1002/14651858.CD006586.pub4.

  53. Pearlstein T.B., Bachmann G.A., Zacur H.A., Yonkers K.A. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation. Contraception. 2005; 72 (6): 414–421. DOI: 10.1016/j.contraception.2005.08.021.

  54. Dilbaz B., Aksan A. Premenstrual syndrome, a common but underrated entity: review of the clinical literature. J. Turk. Ger. Gynecol. Assoc. 2021; 22 (2): 139–148. DOI: 10.4274/jtgga.galenos.2021.2020.0133.

  55. Логинова К.Б., Дюкова Г.М., Доброхотова Ю.Э. Лечение предменструального синдрома и предменструальных дисфорических расстройств комбинированными оральными контрацептивами. Медицинский алфавит. 2018; 33 (4): 13–16.

  56. Аганезова Н.В., Линде В.А. Дифференцированный подход к терапии предменструального синдрома монофазными комбинированными контрацептивами. Журнал акушерства и женских болезней. 2008; 57 (2): 43–52.

  57. Аганезова Н.В. Терапия предменструального синдрома эстроген-гестагенным препаратом, содержащим 20 мкг этинилэстрадиола и 3 мг дроспиренона. Журнал акушерства и женских болезней. 2011; 60 (1): 97–104.

  58. Назарова Н.М., Прилепская В.Н. Эстроген-гестагенные рилизинг-системы: новый взгляд на контрацепцию (обзор литературы). Фарматека. 2009; 14: 10–15.

  59. Milsom I., Lete I., Bjertnaes A., Rokstad K., Lindh I., Gruber C.J., Birkhäuser M.H., Aubeny E., Knudsen T., Bastianelli C. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 µg ethinyl estradiol and 3 mg drospirenone. Human. Reproduction. 2006; 21 (9): 2304–2311. DOI: 10.1093/humrep/del162.

  60. Marjoribanks J., Brown J., O'Brien P.M., Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2013; 2013 (6): CD001396. DOI: 10.1002/14651858.CD001396.pub3.

  61. Freeman E.W., Rickels K., Yonkers K.A., Kunz N.R., McPherson M., Upton G.V. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet. Gynecol. 2001; 98 (5, Pt 1): 737–744. DOI: 10.1016/s0029-7844(01)01530-7.

  62. Pearlstein T.B., Stone A.B., Lund S.A., Scheft H., Zlotnick C., Brown W.A. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. J. Clin. Psychopharmacol. 1997; 17 (4): 261–266. DOI: 10.1097/00004714-199708000-00004.

  63.  Freeman E.W., Rickels K., Sondheimer S.J., Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. Arch. Gen. Psychiatry. 1999; 56 (10): 932–939. DOI: 10.1001/archpsyc.56.10.932.

  64. Eriksson E., Hedberg M.A., Andersch B., Sundblad C. The serotonin reuptake inhibitor paroxetin is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology. 1995; 12 (2): 167–176. DOI: 10.1016/0893-133X(94)00076-C.

  65. Brown J., O'Brien P.M., Marjoribanks J., Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2009; 2: CD001396. DOI: 10.1002/14651858.CD001396.pub2.

  66. Dimmock P.W., Wyatt K.M., Jones P.W., O'Brien P.M. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet. 2000; 356 (9236): 1131–1136. DOI: 10.1016/s0140-6736(00)02754-9.

  67.  Landén M., Nissbrandt H., Allgulander C., Sörvik K., Ysander C., Eriksson E. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology. 2007; 32 (1): 153–161. DOI: 10.1038/sj.npp.1301216.

  68. Соловьева А.Д., Буячинская А.И. Грандаксин в лечении предменструального синдрома. Лечение нервных болезней. 2001; 2 (3): 29–31.

 Поступила в редакцию 08.02.2023; принята 10.07.2023.

 

Автор

Киёк Марина Александровна – врач – акушер-гинеколог, ООО «Медицинский центр «XXI век». 194044, Россия, г. Санкт-Петербург, пр-т Большой Сампсониевский, 45; e-mail: Этот адрес электронной почты защищён от спам-ботов. У вас должен быть включен JavaScript для просмотра., ОRCID ID: https://orcid.org/0000-0002-1539-2559

 

Образец цитирования

Киёк М.А. Предменструальный синдром: основные подходы к лечению. Ульяновский медико-биологический журнал. 2023; 4: 21–37. DOI: 10.34014/2227-1848-2023-4-21-37.